Company Profile
Krystal Biotech Stock Price, News & Analysis
- Ticker:
- KRYS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
322.69 USD (-0.95%)
Close
Last updated: August 6, 2026
8.64B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, KRYS closed down 0.95% at $322.69. No new same-company headline was identified in the current news window.
Company overview
HSV-1 Gene Therapy Platform
Krystal Biotech develops genetic medicines using modified, non-replicating herpes simplex virus type 1 vectors. The platform supports repeat local administration and is being applied to diseases affecting skin, eye and lung tissue.
VYJUVEK Franchise
VYJUVEK is a topical gene therapy approved for wounds in dystrophic epidermolysis bullosa. It provides the commercial and regulatory foundation for Krystal’s platform and is being expanded through launches and reimbursement efforts outside the United States.
KB803 for Corneal Disease
KB803 is being evaluated in the fully enrolled IOLITE registrational study for treatment and prevention of corneal abrasions in patients with dystrophic epidermolysis bullosa. The program applies localized gene delivery to an ocular manifestation of the same genetic disease addressed by VYJUVEK.
KB801 for Neurotrophic Keratitis
KB801 is in the registrational EMERALD-1 study for neurotrophic keratitis. The candidate uses the company’s designated viral-vector platform and represents a second ophthalmic opportunity.
Respiratory and Dermatology Pipeline
KB407 is being developed for cystic fibrosis and KB111 for Hailey-Hailey disease. FDA platform technology designation may allow knowledge from shared vector manufacturing and characterization to support these and future programs.
Future catalysts
Dosing initiation in the KB407 cystic-fibrosis program expected in May 2026.
Topline IOLITE results for KB803 expected in the fourth quarter of 2026.
Completion of EMERALD-1 enrollment and registrational KB801 data expected by year-end 2026.
Potential VYJUVEK launches in Italy and Spain in the second half of 2026, subject to reimbursement.
Recent news
- 01
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
Source: Krystal Biotech
- 02
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
Source: Krystal Biotech
- 03
- 04
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
Source: Krystal Biotech
- 05
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
Source: Krystal Biotech
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Krystal Biotech (KRYS)?
Krystal Biotech (KRYS) most recently closed at 322.69 USD, a -0.95% move versus the previous session.
What is the market cap of Krystal Biotech (KRYS)?
Krystal Biotech currently has a market capitalization of 8.64B USD on BioPharmSignal.
What does Krystal Biotech do?
HSV-1 Gene Therapy Platform Krystal Biotech develops genetic medicines using modified, non-replicating herpes simplex virus type 1 vectors. The platform supports repeat local administration and is being applied to diseases affecting skin, eye and lung tissue. VYJUVEK Franchise VYJUVEK is a topical gene therapy approved for wounds in dystrophic epidermolysis...
On which exchange is KRYS stock listed?
Krystal Biotech (KRYS) is associated with NASDAQ, United States, Biopharma.
What is HSV-1?
HSV-1 Gene Therapy Platform Krystal Biotech develops genetic medicines using modified, non-replicating herpes simplex virus type 1 vectors.
Which conditions is Krystal Biotech targeting with HSV-1?
Krystal Biotech is associated with dermatology, respiratory disease, genetic disease based on its company overview and current catalyst commentary.
How does Krystal Biotech describe recent progress with HSV-1?
Dosing initiation in the KB407 cystic-fibrosis program expected in May 2026. Topline IOLITE results for KB803 expected in the fourth quarter of 2026. Completion of EMERALD-1 enrollment and registrational KB801 data expected by year-end 2026. Potential VYJUVEK launches in Italy and Spain in the second half of 2026, subject to reimbursement.
What is EMERALD-1?
KB801 for Neurotrophic Keratitis KB801 is in the registrational EMERALD-1 study for neurotrophic keratitis.